scholarly journals Do lamotrigine and levetiracetam solve the problem of using sodium valproate in women with epilepsy?

2012 ◽  
Vol 5 (1) ◽  
pp. 6-13
Author(s):  
John J Craig
Keyword(s):  
Adverse Effects ◽  
Antiepileptic Drug ◽  
Sodium Valproate ◽  
Broad Spectrum ◽  
Current Information ◽  
Drug Of Choice ◽  
Child Bearing ◽  
Seizure Syndrome

Women with epilepsy, especially those of child-bearing age, are faced with difficult choices when it comes to choosing the most suitable antiepileptic drug (AED). This is particularly so for those with idiopathic generalized epilepsies, or those for whom seizure syndrome is not immediately apparent, where sodium valproate is still considered the drug of choice. While with treatment most might expect to become seizure free, without any adverse effects, other considerations for women mean that valproate is usually initially avoided, with other AEDs such as lamotrigine or levetiracetam being chosen in preference. Based on current information, this article attempts to provide an overview on whether or not the availability of these and other broad-spectrum AEDs have solved the difficulties of using valproate in women of child-bearing age.

scholarly journals Rufinamide: A Novel Broad-Spectrum Antiepileptic Drug

2010 ◽  
Vol 10 (1) ◽  
pp. 1-6 ◽  
Author(s):  
James W. Wheless ◽  
Blanca Vazquez
Keyword(s):  
Antiepileptic Drug ◽  
Broad Spectrum

Lack of relationship between sodium valproate-induced adverse effects and the plasma concentration of its metabolite 2-propylpenten-4-oic acid

1987 ◽  
Vol 32 (2) ◽  
pp. 219-222 ◽  
Author(s):  
M. Paganini ◽  
G. Zaccara ◽  
F. Moroni ◽  
R. Campostrini ◽  
L. Bendoni ◽  
...  
Keyword(s):  
Plasma Concentration ◽  
Adverse Effects ◽  
Sodium Valproate

Level of physicians' awareness of antiepileptic drug adverse effects

2018 ◽  
Vol 89 ◽  
pp. 59-62
Author(s):  
Ameen Mosleh Almohammadi ◽  
Ruqayah Mohamed Huzaim
Keyword(s):  
Adverse Effects ◽  
Antiepileptic Drug ◽  
Drug Adverse Effects

scholarly journals Antimicrobial Activity of Biosynthesized Silver Nanoparticles Compared to Standard Antibiotics Used in ORL Infections

2019 ◽  
Vol 70 (7) ◽  
pp. 2571-2573
Author(s):  
Alina Andreea Tischer (Tucuina) ◽  
Delia Berceanu Vaduva ◽  
Nicolae Balica ◽  
Alina Heghes ◽  
Adelina Cheveresan ◽  
...  
Keyword(s):  
Antimicrobial Activity ◽  
Silver Nanoparticles ◽  
Antibiotic Resistance ◽  
Adverse Effects ◽  
Infectious Diseases ◽  
Broad Spectrum ◽  
Bacterial Infections ◽  
New Antibiotics ◽  
Recorded Data

In recent years, bacterial infections in hospitals have grown particularly due to the development of antibiotic resistance. Recent research targets the discovery of new antibiotics that exhibit broad spectrum of action without adverse effects or minimizing adverse effects. In this study, the activity of biosynthesized silver nanoparticles against three bacteria commonly found in infectious diseases in the ORL sphere was evaluated. The recorded data revealed an activity comparable to that of the standard antibiotics used in these types of infections, with the observation that the activity of the nanoparticles could also be observed in the particular cases of antibiotic resistance.

S

2020 ◽  
pp. 718-772
Author(s):  
Sean Ainsworth
Keyword(s):  
Sodium Chloride ◽  
Adverse Effects ◽  
Sodium Bicarbonate ◽  
Sodium Valproate ◽  
Fusidic Acid ◽  
Sodium Benzoate ◽  
Skin Care ◽  
Maternal Treatment ◽  
Sodium Phenylbutyrate

This chapter presents information on neonatal drugs that begin with S, including use, pharmacology, adverse effects, fetal and infant implications of maternal treatment, treatment, and supply of Salbutamol = Albuterol (USAN), Sildenafil, Skin care and skin sterility, Sodium phenylbutyrate and glycerol phenylbutyrate, Sodium benzoate, Sodium bicarbonate, Sodium chloride, Sodium fusidate (fusidic acid), Sodium valproate, Sotalol, Spiramycin, Spironolactone, Stiripentol, Streptokinase, Sucrose, Sulfadiazine = Sulphadiazine (former BAN), Surfactants, and Suxamethonium = Succinylcholine (USAN)

scholarly journals Treatment of epilepsy – towards precision

F1000Research ◽  
2018 ◽  
Vol 7 ◽  
pp. 1932 ◽  
Author(s):  
John Paul Leach
Keyword(s):  
Genetic Testing ◽  
Adverse Effects ◽  
Drug Treatment ◽  
Antiepileptic Drug ◽  
Precision Medicine ◽  
Treatment Of Epilepsy ◽  
Antiepileptic Drug Treatment

Epilepsy was among the first disease areas to begin to apply principles of precision medicine to its treatment. This review looks at the role of investigation in ensuring the safety and effectiveness of antiepileptic drug treatment. Using sound principles, we can see that the use of genetic testing will advance treatment of epilepsy in reducing harm and adverse effects and enhancing efficacy.

Delirium on clozapine: A tale of friend turned foe-A case report

2020 ◽  
pp. 009121742097282 ◽  
Author(s):  
Aparna Das ◽  
Rebecca Minner ◽  
Lewis Krain ◽  
John Spollen
Keyword(s):  
Case Report ◽  
Clinical Practice ◽  
Side Effects ◽  
Adverse Effects ◽  
Older Adult ◽  
Psychiatric Illness ◽  
Management Strategies ◽  
Treatment Resistant ◽  
Drug Of Choice ◽  
Life Threatening

Treatment resistant schizophrenia (TRS) is often encountered in clinical practice. Clozapine remains the drug of choice in the management of TRS. Several studies have shown that clozapine is the most effective antipsychotic medication to date for TRS. But it is also well known that it has multiple side effects. Some side effects are transient and relatively benign, while other adverse effects are menacing, serious and life-threatening. Delirium may occur with clozapine and is a therapeutic challenge as there is always a risk of precipitating delirium on clozapine rechallenge. Limited management strategies are available as alternatives for the management of psychiatric illness stabilized on clozapine. In this case report, we describe an older adult patient who developed delirium on clozapine. The aims of this case report are to discuss the mechanism by which clozapine leads to delirium, revisit various factors which could possibly lead to delirium, and discuss the different management strategies available for management of psychiatric illness for a patient previously stabilized on clozapine.

Zonisamide

2018 ◽  
Author(s):  
Andrea E. Cavanna
Keyword(s):  
Bipolar Disorder ◽  
Weight Gain ◽  
Adverse Effects ◽  
Alcohol Dependence ◽  
Antiepileptic Drug ◽  
Preliminary Evidence ◽  
Tolerability Profile ◽  
Patients With Epilepsy ◽  
Psychiatric Adverse Effects ◽  
Acceptable Tolerability Profile

Zonisamide is a second-generation antiepileptic drug characterized by a few antiepileptic indications, with an acceptable interaction profile in polytherapy. Zonisamide has an acceptable tolerability profile in patients with epilepsy, with depression, irritability, agitation and psychosis as the most commonly reported psychiatric adverse effects. Zonisamide has no approved indications or clinical uses in psychiatry, as initial findings from uncontrolled studies suggesting effectiveness in the treatment of patients with bipolar disorder did not find confirmation. There is preliminary evidence for possible usefulness of zonisamide in the treatment of patients with obesity and psychotropic-associated weight gain, as well as alcohol dependence and withdrawal.

Vigabatrin

2018 ◽  
Author(s):  
Andrea E. Cavanna
Keyword(s):  
Adverse Effects ◽  
Antiepileptic Drug ◽  
Routine Clinical Practice ◽  
Visual Field Defects ◽  
Tolerability Profile ◽  
Psychiatric History ◽  
Weak Evidence ◽  
Patients With Epilepsy ◽  
Psychiatric Adverse Effects ◽  
Field Defects

Vigabatrin is a second-generation antiepileptic drug characterized by a few antiepileptic indications, with a very good interaction profile in polytherapy. Clinically relevant adverse effects (especially visual field defects) have reduced its use as antiepileptic drug in routine clinical practice considerably. Vigabatrin has an acceptable behavioural tolerability profile, although patients with epilepsy treated with this medication can report depression, psychosis, and irritability. Risk factors for developing psychiatric adverse effects include high starting and maintenance doses, past psychiatric history, and epilepsy severity. Vigabatrin has no approved indications or clinical uses in psychiatry, despite weak evidence for its usefulness in the treatment of anxiety disorders and addictions.

Sign in / Sign up

Export Citation Format

Share Document